Amryt Pharma PLC - biopharmaceutical company focused on developing novel treatments for rare diseases - Ups 2021 guidance to reflect the success of recent acquisition Chiasma Inc. Increases full-year revenue guidance to between USD220 million and USD225 million, representing growth of 20% to 23% on 2020. Previous guidance issued in August predicted revenue of between USD210 million and USD215 million, the company notes.
Chief Executive Joe Wiley says: "This latest upward revision of guidance demonstrates our confidence in the outlook for our underlying business and our visibility is further enhanced given that we have now begun the process of integrating Chiasma into Amryt and have begun to grow our combined business."
Current stock price: closed at 159.00 pence on Monday
Year-to-date change: down 16%
By Scarlett Butler; scarlettbutler@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
